Sequenta Receives CLIA Certification | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenta said today it has received CLIA certification for a clinical test based on in its immune repertoire sequencing-based technology called LymphoSight.

"Full clonality analysis of immune cell repertoires will have applications in the diagnosis and management of many blood cancers," Sequenta CEO Tom Willis said in a statement. "With CLIA certification, we are now able to use the LymphoSight method and make these clinical tests available to the physician community."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.